SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

This early-stage study tests a new cell therapy called YTS109 in 12 children aged 5 to 17 with severe autoimmune diseases like lupus and scleroderma that haven't responded to standard treatments. The therapy is given as a single IV infusion, and the main goals are to check its sa…

This early-stage study tests whether a single infusion of a patient's own modified immune cells (CAR-T cells) is safe for people with severe autoimmune diseases like lupus, rheumatoid arthritis, and scleroderma that haven't responded to standard treatments. The study will closely…

This early-stage trial tests a new treatment made from a patient's own immune cells, modified to target and destroy faulty cells that cause lupus. It is for 20 people aged 16-70 whose lupus has not improved with at least two standard treatments. The goal is to see if it is safe a…

This study tests a new drug, SCTC21C, in 159 adults with systemic lupus erythematosus (SLE). The goal is to see if it is safe and can help control the disease. Participants must have moderate to severe lupus and be on standard treatments. The study is in two parts: first checking…

This study tests a new drug called HC022 in 32 people with lupus (SLE or CLE). The main goal is to see if it is safe and how the body handles it. Participants will receive multiple doses of the drug or a placebo. This is an early-stage trial, so it focuses on safety and dosing, n…

This study will follow about 700 adults recently diagnosed with lupus across Europe for up to 5 years. Researchers want to see how many patients reach low disease activity or remission in the first year, and find markers in blood or urine that predict how the disease will progres…

This study looks at 400 people with lupus to compare those with typical symptoms (like joint pain and rash) to those with unusual or late-onset symptoms. The goal is to see if atypical cases lead to worse outcomes, more organ damage, or different treatment needs. By understanding…

This study compares blood levels of two molecules (microRNA-101-3p and autotaxin) between 40 adults with lupus and healthy volunteers. Researchers want to see if these markers are linked to lupus activity and could one day be used as simple blood tests to monitor the disease. No …